EA202092294A1 - Гетероциклическое соединение и его применение - Google Patents

Гетероциклическое соединение и его применение

Info

Publication number
EA202092294A1
EA202092294A1 EA202092294A EA202092294A EA202092294A1 EA 202092294 A1 EA202092294 A1 EA 202092294A1 EA 202092294 A EA202092294 A EA 202092294A EA 202092294 A EA202092294 A EA 202092294A EA 202092294 A1 EA202092294 A1 EA 202092294A1
Authority
EA
Eurasian Patent Office
Prior art keywords
applications
heterocyclic compounds
relates
present
compound
Prior art date
Application number
EA202092294A
Other languages
English (en)
Inventor
Юя Огуро
Сигемицу Мацумото
Такеси Вакабаяси
Норихито Токунага
Таку Камеи
Мицухиро Ито
Сатоси Миками
Масаки Сето
Синдзи Моримото
Синдзи Накамура
Сатие Такасима
Масатака Мураками
Масаки Даини
Макото Камата
Минору Накамура
Ясуфуми Вада
Хироюки Какеи
Кадзуаки Таками
Таисуке Тавараиси
Дзумпей Айда
Коуити Иванага
Сатоси Ямамото
Original Assignee
Такеда Фармасьютикал Компани Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Такеда Фармасьютикал Компани Лимитед filed Critical Такеда Фармасьютикал Компани Лимитед
Publication of EA202092294A1 publication Critical patent/EA202092294A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Настоящее изобретение относится к гетероциклическому соединению, оказывающему антагонистическое воздействие на рецептор NMDA, содержащий субъединицу NR2B, и предположительно применимому в качестве средства для профилактики или лечения большой депрессии, биполярного расстройства, мигрени, боли, поведенческих и психологических симптомов слабоумия и т.п. Настоящее изобретение относится к соединению, описывающемуся формулой (I)где каждый символ является таким, как описано в описании, или его соли.
EA202092294A 2018-03-28 2019-03-27 Гетероциклическое соединение и его применение EA202092294A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018062939 2018-03-28
PCT/JP2019/014901 WO2019189945A1 (en) 2018-03-28 2019-03-27 Heterocyclic compound and use thereof

Publications (1)

Publication Number Publication Date
EA202092294A1 true EA202092294A1 (ru) 2021-01-15

Family

ID=66397395

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202092294A EA202092294A1 (ru) 2018-03-28 2019-03-27 Гетероциклическое соединение и его применение

Country Status (16)

Country Link
US (2) US10807987B2 (ru)
EP (1) EP3774800A1 (ru)
JP (1) JP7279067B2 (ru)
KR (1) KR20200136957A (ru)
CN (1) CN111936495A (ru)
AR (1) AR115020A1 (ru)
AU (1) AU2019241765B2 (ru)
BR (1) BR112020018238A2 (ru)
CA (1) CA3100133A1 (ru)
EA (1) EA202092294A1 (ru)
IL (1) IL276912A (ru)
MA (1) MA52214A (ru)
MX (1) MX2020010148A (ru)
SG (1) SG11202008519RA (ru)
TW (1) TW202003519A (ru)
WO (1) WO2019189945A1 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019022179A1 (ja) 2017-07-28 2019-01-31 武田薬品工業株式会社 複素環化合物
AU2019241765B2 (en) * 2018-03-28 2022-07-07 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
JP2021050161A (ja) 2019-09-25 2021-04-01 武田薬品工業株式会社 複素環化合物及びその用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2492382A1 (fr) * 1980-10-22 1982-04-23 Synthelabo Derives d'imidazo (1,2-a) pyridine, leur preparation et leur application en therapeutique
US5252563A (en) * 1991-12-19 1993-10-12 G. D. Searle & Company 5,6,7,8-tetrahydro-imidazo[1,2-a]pyrimidine compounds for treatment of neurotoxic injury
JP3439551B2 (ja) * 1994-11-08 2003-08-25 富士写真フイルム株式会社 ハロゲン化銀写真感光材料
EP0815134B1 (en) 1995-03-14 2002-06-05 Praecis Pharmaceuticals Incorporated Modulators of amyloid aggregation
EP1586584A1 (en) 1996-08-27 2005-10-19 Praecis Pharmaceuticals Incorporated Modulators of beta-amyloid peptide aggregation comprising D-amino acids
US6331640B1 (en) 1998-10-13 2001-12-18 Hoffmann-La Roche Inc. Diaminopropionic acid derivatives
CA2374610A1 (en) 1999-06-28 2001-01-04 Jordan J. N. Tang Catalytically active recombinant memapsin and methods of use thereof
CA2443108A1 (en) * 2001-04-03 2002-10-17 Merck & Co. Inc. N-substituted nonaryl-heterocyclo amidyl nmda/nr2b antagonists
JP2004161716A (ja) * 2002-11-15 2004-06-10 Takeda Chem Ind Ltd Ｊｎｋ阻害剤
EP1615636A1 (en) * 2003-04-10 2006-01-18 Pfizer Inc. Bicyclic compounds as nr2b receptor antagonists
US20080234318A1 (en) 2005-08-31 2008-09-25 Kristjan Gudmundsson Chemical Compounds
MX2011008276A (es) * 2009-02-06 2011-12-14 Elan Pharm Inc Inhibidores de quinasa jun n-terminal.
US8404859B2 (en) 2011-03-16 2013-03-26 Hoffmann-La Roche Inc. Thiazole and thiophene compounds
KR20130133905A (ko) * 2011-04-05 2013-12-09 화이자 리미티드 트로포미오신-관련 키나제의 억제제인 피롤로[2,3-d]피리미딘 유도체
FR2998892B1 (fr) 2012-12-04 2015-01-02 Pf Medicament Derives d'aminocyclobutane, leur procede de preparation et leur utilisation a titre de medicaments
AU2014254392B2 (en) 2013-03-15 2018-05-24 Epizyme, Inc. Substituted benzene compounds
US9243001B2 (en) 2013-03-15 2016-01-26 Epizyme, Inc. Substituted benzene compounds
US10202376B2 (en) 2014-12-24 2019-02-12 Takeda Pharmaceutical Company Limited Heterocyclic compound
JP6827757B2 (ja) 2016-10-11 2021-02-10 鬼怒川ゴム工業株式会社 ウエザーストリップ取付用クリップ
WO2019022179A1 (ja) 2017-07-28 2019-01-31 武田薬品工業株式会社 複素環化合物
AU2019241765B2 (en) * 2018-03-28 2022-07-07 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
JPWO2020153414A1 (ja) 2019-01-24 2021-12-02 武田薬品工業株式会社 複素環化合物及びその用途
WO2020196828A1 (ja) 2019-03-28 2020-10-01 武田薬品工業株式会社 含窒素複素環化合物

Also Published As

Publication number Publication date
CN111936495A (zh) 2020-11-13
WO2019189945A1 (en) 2019-10-03
SG11202008519RA (en) 2020-10-29
US10807987B2 (en) 2020-10-20
BR112020018238A2 (pt) 2020-12-29
JP2021519294A (ja) 2021-08-10
TW202003519A (zh) 2020-01-16
AU2019241765A8 (en) 2021-02-18
JP7279067B2 (ja) 2023-05-22
US20210332053A1 (en) 2021-10-28
AU2019241765B2 (en) 2022-07-07
AU2019241765A1 (en) 2020-11-12
CA3100133A1 (en) 2019-10-03
US20190300536A1 (en) 2019-10-03
KR20200136957A (ko) 2020-12-08
IL276912A (en) 2020-10-29
MA52214A (fr) 2021-04-21
MX2020010148A (es) 2020-12-07
AR115020A1 (es) 2020-11-18
US11702419B2 (en) 2023-07-18
WO2019189945A8 (en) 2020-10-15
EP3774800A1 (en) 2021-02-17

Similar Documents

Publication Publication Date Title
EA201992253A1 (ru) Новые гетероциклические производные, применимые в качестве ингибиторов shp2
EA202091479A1 (ru) Арил- и гетероарилзамещенные индольные соединения
EA201990851A1 (ru) Новые аналоги карбануклеозида, замещенные моноциклической и бициклической кольцевой системой, для применения в качестве ингибиторов prmt5
EA202091474A1 (ru) Замещенные индольные соединения, применимые в качестве ингибиторов tlr
EA202091484A1 (ru) 4-азаиндольные соединения
EA202091893A1 (ru) Новые кристаллические формы
EA201992322A2 (ru) Соединения и композиции для лечения гематологических расстройств
EA202092294A1 (ru) Гетероциклическое соединение и его применение
EA202090256A1 (ru) 5-членные и бициклические гетероциклические амиды в качестве ингибиторов rock
EA201591051A1 (ru) Ингибиторы erk и варианты их применения
GEP20227443B (en) Magl inhibitors
EA202090688A1 (ru) Бис-амидные соединения, активирующие саркомер, и варианты их применения
EA201891930A1 (ru) Способы лечения депрессии с использованием антагонистов орексиновых рецепторов-2
MX2019002438A (es) Compuestos triciclicos fusionados de piridazinona utiles para tratar infecciones de orthomyxovirus.
EA202091477A1 (ru) Замещенные соединения простых индольных эфиров
MD3386991T2 (ro) Compuși policiclici ca inhibitori de tirozin kinază Bruton
EA202190464A1 (ru) Замещенные бензимидазолы в качестве ингибиторов pad4
EA201891644A1 (ru) Антибактериальные соединения и их применение
EA202090119A1 (ru) Аморфные и кристаллические формы ido-ингибиторов
EA201890448A1 (ru) Фумагиллиновые спироциклические соединения и конденсированные бициклические соединения и способы их получения и применения
MX2020006307A (es) Compuesto ciclico de 6 miembros que contiene nitrogeno.
MX2019013979A (es) Metodos para la preparacion de compuestos heterociclicos de 1,3-benzodioxol.
EA201992259A1 (ru) Замещенные n-(1,3,4-оксадиазол-2-ил)арилкарбоксамиды и их применение в качестве гербицидов
EA202190356A1 (ru) Композиции и способы лечения расстройств, ослабляемых активацией мускариновых рецепторов
EA201390180A1 (ru) Конденсированные циклические соединения пиридина